LSTA
Income statement / Annual
Last year (2023), Lisata Therapeutics, Inc.'s total revenue was $0.00,
a decrease of 100.00% from the previous year.
In 2023, Lisata Therapeutics, Inc.'s net income was -$20.84 M.
See Lisata Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$0.00
|
$121.37 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$35.28 M
|
$22.49 M
|
$17.94 M
|
| Cost of Revenue |
$189,000.00 |
$57.60 M |
$55,000.00 |
$63,000.00 |
$65,000.00 |
$225,000.00 |
$372,000.00 |
$31.14 M |
$20.16 M |
$15.68 M |
| Gross Profit |
-$189,000.00 |
$63.77 M |
-$55,000.00 |
-$63,000.00 |
-$65,000.00 |
-$225,000.00 |
-$372,000.00 |
$4.15 M |
$2.33 M |
$2.26 M |
| Gross Profit Ratio |
0 |
0.53 |
0 |
0 |
0 |
0 |
0 |
0.12 |
0.1 |
0.13 |
| Research and Development
Expenses |
$12.73 M
|
$43.46 M
|
$17.68 M
|
$9.25 M
|
$10.80 M
|
$7.59 M
|
$15.84 M
|
$15.11 M
|
$23.90 M
|
$29.19 M
|
| General & Administrative
Expenses |
$12.97 M
|
$14.14 M
|
$11.37 M
|
$9.89 M
|
$9.30 M
|
$9.39 M
|
$11.75 M
|
$12,802.00
|
$0.00
|
$0.00
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$20.36 M
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$12.97 M
|
$14.14 M
|
$11.37 M
|
$9.89 M
|
$9.30 M
|
$9.39 M
|
$11.75 M
|
$20.37 M
|
$30.01 M
|
$30.81 M
|
| Other Expenses |
$0.00 |
-$155,000.00 |
-$75,000.00 |
$132,000.00 |
$740,000.00 |
$824,000.00 |
$273,101.00 |
$21,957.00 |
$17.72 M |
$2.93 M |
| Operating Expenses |
$25.71 M |
$57.60 M |
$29.05 M |
$19.15 M |
$20.09 M |
$16.99 M |
$27.59 M |
$35.48 M |
$53.90 M |
$60.00 M |
| Cost And Expenses |
$25.71 M |
$57.60 M |
$29.05 M |
$19.15 M |
$20.09 M |
$16.99 M |
$27.59 M |
$66.62 M |
$74.06 M |
$75.68 M |
| Interest Income |
$2.72 M |
$1.05 M |
$151,000.00 |
$132,000.00 |
$740,000.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$0.00 |
-$1.95 M |
$0.00 |
$0.00 |
$0.00 |
$5,000.00 |
$377,768.00 |
$1.86 M |
$2.13 M |
$755,697.00 |
| Depreciation &
Amortization |
$189,000.00
|
$69,000.00
|
$55,000.00
|
$63,000.00
|
$65,000.00
|
$225,000.00
|
$372,000.00
|
$450,266.00
|
$2.69 M
|
$2.19 M
|
| EBITDA |
-$25.52 M
|
-$115.20 M
|
-$29.00 M
|
-$19.08 M
|
-$20.03 M
|
-$16.76 M
|
-$27.22 M
|
-$29.03 M
|
-$93.44 M
|
-$52.63 M
|
| EBITDA Ratio |
0 |
-0.48 |
0 |
0 |
0 |
0 |
0 |
-0.81 |
-1.39 |
-2.93 |
| Operating Income Ratio
|
0
|
-0.47
|
0
|
0
|
0
|
0
|
0
|
-0.89
|
-5.06
|
-3.22
|
| Total Other
Income/Expenses Net |
$2.54 M
|
$897,000.00
|
$76,000.00
|
$132,000.00
|
$740,000.00
|
$819,000.00
|
-$104,706.00
|
$78,007.00
|
$15.59 M
|
$2.17 M
|
| Income Before Tax |
-$23.17 M |
-$56.70 M |
-$28.97 M |
-$19.01 M |
-$19.35 M |
-$16.17 M |
-$27.70 M |
-$33.17 M |
-$98.25 M |
-$55.57 M |
| Income Before Tax Ratio
|
0
|
-0.47
|
0
|
0
|
0
|
0
|
0
|
-0.94
|
-4.37
|
-3.1
|
| Income Tax Expense |
-$2.33 M |
-$2.48 M |
-$1.51 M |
-$10.87 M |
$749,000.00 |
-$1,000.00 |
-$11.53 M |
$138,038.00 |
-$17.24 M |
-$104,202.00 |
| Net Income |
-$20.84 M |
-$54.23 M |
-$27.47 M |
-$8.14 M |
-$20.10 M |
-$16.17 M |
$22.98 M |
-$32.66 M |
-$80.89 M |
-$54.87 M |
| Net Income Ratio |
0 |
-0.45 |
0 |
0 |
0 |
0 |
0 |
-0.93 |
-3.6 |
-3.06 |
| EPS |
-2.58 |
-10.47 |
-7.45 |
-7.91 |
-29.2 |
-25.03 |
38.43 |
-74.81 |
-250.12 |
-251.28 |
| EPS Diluted |
-2.58 |
-10.47 |
-7.45 |
-7.91 |
-29.2 |
-25.03 |
38.43 |
-74.81 |
-250.12 |
-251.28 |
| Weighted Average Shares
Out |
$8.07 M
|
$5.18 M
|
$3.69 M
|
$1.03 M
|
$688,333.00
|
$645,933.00
|
$597,933.00
|
$436,550.00
|
$323,387.00
|
$218,374.00
|
| Weighted Average Shares
Out Diluted |
$8.07 M
|
$5.18 M
|
$3.69 M
|
$1.03 M
|
$688,333.00
|
$645,933.00
|
$597,933.00
|
$436,550.00
|
$323,387.00
|
$218,374.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
